WARRANT
FDA Warning Letter Remediation Control
DOCKET // WR–DEMO–04471 000% ILLUSTRATIVE OPERATIONAL MODEL
FDA Warning Letter Remediation Exhibit 00

The warning letter is not the problem. What's still unresolved behind it is.

After a warning letter, open commitments may sit in complaints, corrective actions, audits, supplier controls, and training records — scattered across staff, counsel, and consultants, with no single reliable record of what is done, what remains open, and who owns each item.

0 Response period (cited letter)
0 Device warning letters FY25
0% Concerned the QSR
Fig. 01 — Illustrative pre-engagement state ● Live
SINGLE LEDGER NOT YET BUILT COMPLAINTS CAPA AUDITS SUPPLIER CONTROLS OVERDUE TRAINING RECORDS STATUS UNKNOWN
5 disconnected sources 0 unified record

Illustrative structure of a pre-engagement state. Does not provide legal or regulatory advice. Demonstration only — not a client case.

Exhibit 01 / Context

Quality system deficiencies are the throughline in almost every recent device warning letter.

In FY2025, 38 of 44 FDA warning letters to medical-device manufacturers concerned the Quality System Regulation. The five most frequently cited QSR deficiency categories were CAPA, design controls, complaint files, purchasing controls, and process validation.

44
FY25 / Device WLs 0

Warning letters issued to medical-device manufacturers in fiscal year 2025.

Source: ECA / GMP Compliance
86%
QSR deficiencies 0 / 44

Warning letters concerning the Quality System Regulation. The most frequently cited categories were CAPA, design controls, complaint files, purchasing controls, and process validation.

Source: ECA / GMP Compliance

Historical FY2025 figures refer to the Quality System Regulation then in force. The Quality Management System Regulation became effective February 2, 2026.

15
Response period 0

15-business-day response period in the cited representative letter. FDA commonly asks for a written response identifying corrective steps taken and planned, with supporting documentation.

When actions cannot be completed within the response period, the company may explain the delay and provide an implementation timetable.

Source: FDA warning letter (representative example)
DEADLINE
Exhibit 02 / The response period

Fifteen business days. The cited response period begins immediately.

FDA commonly asks for a written response identifying corrective steps taken and planned, with supporting documentation. When actions cannot be completed in period, the company may explain the delay and provide a timetable.

When remediation is fragmented across internal staff, counsel, and consultants, leadership may lack one reliable view of completed actions, open commitments, ownership, evidence, and timetables.

0 Illustrative consolidation period
0 Illustrative remaining response period

Illustrative response scenario — not an industry benchmark.

Illustrative response scenario — not an industry benchmark ● Running
D01
D02
D03
D04
D05
D06
D07
D08
D09
D10
D11
D12
D13
D14
D15
Day 1–7 Illustrative consolidation period Inventory fragmented across systems. No single reliable record.
Day 8 — Illustrative crossover Operational control engaged Controlled record established. Owners assigned. Evidence trail begun.
Day 9–15 Response support Available evidence organized, open actions and timetables recorded, response package supported. Submission remains with the client and its counsel or regulatory lead.
EXPOSURE
Exhibit 03 / Compounding exposure

Waiting compounds it.

When remediation is fragmented across internal staff, counsel, and consultants, leadership may lack one reliable view of completed actions, open commitments, ownership, evidence, and timetables.

The cost rarely shows up as a line item. It can show up as manufacturing held for an audit response, product on hold during a complaint investigation, and senior staff re-tracing work because no reliable record was maintained.

The mandate establishes operational control before the response is due and continues tracking open remediation work afterward.

Can your leadership currently identify every in-scope commitment, its accountable owner, its supporting evidence, and its remaining timetable from one reliable record?

Possible consequence 01

Manufacturing may be held for an audit response without organized evidence readily available.

Possible consequence 02

Product may remain on hold during a complaint investigation with no clear closure path.

Possible consequence 03

Senior staff may re-trace work because no reliable record of completed actions was maintained.

MANDATE
Exhibit 04 / The mandate

One operation. Every in-scope item accounted for.

Warrant establishes the operational control layer during the initial response period and, when scoped, continues coordinating and tracking remediation actions that extend beyond the initial response.

Regulatory judgments remain with the client's qualified specialists or counsel. Warrant records the decision, assigns the resulting operational work, tracks dependencies, and maintains the evidence trail.

01 Phase

Inventory & Prioritization

Every in-scope remediation item identified from the relevant complaint, CAPA, audit, supplier, training, and related records is logged in one controlled record.

  • +In-scope item inventory
  • +Owner and deadline on every item
  • +Prioritized per client-approved criteria
Phase 01
02 Phase

Ownership & Routing

Every in-scope item gets one accountable name. Regulatory decisions are routed to the client's qualified specialists or counsel — not a generalist, and not whoever's available.

  • +Named owner per item
  • +Regulatory decisions routed to qualified specialists
  • +Internal and external work, tracked together
Phase 02
03 Phase

Closure Evidence

No in-scope item is marked complete until its required closure evidence has been reviewed. Additional sampling is performed where the agreed verification plan calls for it.

  • +Required closure evidence reviewed before status changes
  • +Sampling used only where defined in the verification plan
  • +Items reopened when evidence does not support closure
Phase 03
04 Phase

Reporting & Evidence

A standing weekly report shows what's complete, blocked, overdue, or still carrying open commitments — in terms your COO or CEO can act on.

  • +Weekly report, one point of accountability
  • +Live status on every in-scope item
  • +Evidence file built continuously, not reconstructed later
Phase 04
LEDGER
Exhibit 05 / The ledger

The ledger.

Every in-scope item in your remediation lives on one controlled record — status, owner, and evidence, visible to whoever needs to see it.

Illustrative
Ref Item Owner Status Evidence
CMP-4471Complaint investigationJ. Alvarez, QualityEvidence pending2 of 3
CAPA-118Supplier corrective actionExternal specialistEvidence complete5 of 5
AUD-07Internal quality auditT. Nguyen, QualityIn review3 of 4
TRN-22Employee training recordsHR / QualityClosed8 of 8
SUP-03Supplier control assessmentExternal specialistOverdue0 of 3

Illustrative excerpt. Every engagement's ledger is built from the client's actual files. Demonstration only — not a client case.

Exhibit 06 / Evidence standard

Nothing is marked complete without the required evidence.

OPERATIONAL CONTROL, NOT REGULATORY ADVICE / NO OUTCOME PROMISED OR IMPLIED / EVERY ITEM OWNED AND EVIDENCED / NOTHING MARKED COMPLETE WITHOUT EVIDENCE / OPERATIONAL CONTROL, NOT REGULATORY ADVICE / NO OUTCOME PROMISED OR IMPLIED / EVERY ITEM OWNED AND EVIDENCED / NOTHING MARKED COMPLETE WITHOUT EVIDENCE /
WR-DEMO-04471 ● ILLUSTRATIVE OPERATIONAL MODEL ● DOES NOT PROVIDE LEGAL OR REGULATORY ADVICE ● NO OUTCOME WITH FDA IS PROMISED OR IMPLIED ● WR-DEMO-04471 ● ILLUSTRATIVE OPERATIONAL MODEL ● DOES NOT PROVIDE LEGAL OR REGULATORY ADVICE ● NO OUTCOME WITH FDA IS PROMISED OR IMPLIED ●

Warrant provides operational coordination, tracking, evidence control, and reporting. It does not provide legal or regulatory advice and does not replace the client's counsel or qualified regulatory specialists. No outcome with FDA is promised or implied. What Warrant provides is a controlled record of what has been done, what remains open, and what evidence supports each item.

FIT
Exhibit 07 / Qualification

Who this is built for.

The scope is bounded on purpose. That only works if the fit is right before day one.

Built for
  • +A recent FDA warning letter with open remediation items across complaints, CAPA, audits, supplier controls, training, or related records
  • +Response work already spread across internal staff, outside counsel, and regulatory consultants
  • +A named VP or Director of Quality Systems or Regulatory Affairs who can sponsor the engagement, with COO or CEO sign-off
  • +A need for one reliable record showing what is done, what remains open, and who owns each item
Not a fit if
  • −The underlying issue is a product or design defect, not an operational tracking gap. That's a different problem than this mandate addresses
  • −No one internally owns the remediation decision
  • −Looking for regulatory strategy or legal representation. Warrant coordinates and tracks the operation your specialists work inside of — it does not replace them
  • −Not prepared to have an organized, evidenced response file by the time it's due
SCOPE
CONTACT
Exhibit 09 / Scoping request

Request a Response-Control Scoping Session.

In the scoping session, we determine whether your current bottleneck is regulatory judgment or operational control, identify the principal ownership and evidence gaps visible from the materials you share, and establish whether a bounded mandate is possible. You leave with a clear fit/no-fit decision and a preliminary scope — not a generic pitch.

Docket WR–DEMO–04471
Model Illustrative operational model
Response We generally respond within one business day
Channel Direct, scheduled call

Engagements are confidential. This form is a starting point, not a commitment.